IMW 2021 | Combining expert opinion and trial data to predict survival for myeloma patients receiving ide-cel
Parameswaran Hari, MD, MRCP, MS, of the Froedtert Hospital Cancer Center, Milwaukee, WI, gives an overview of his poster presentation at the IMW 2021 meeting on the findings of a prospective qualitative study which combined expert opinions with data from the KarMMa trial (NCT03361748), the retrospective KarMMa-RW study and the MAMMOTH study to estimate survival rates at three, five and 10 years for patients with multiple myeloma receiving idecabtagene vicleucel (ide-cel). The KarMMa trial, a Phase II trial investigated the use of ide-cel, a B-cell maturation antigen (BCMA) directed chimeric antigen receptor T-cell (CAR-T) therapy, for the treatment of patients with relapsed/refractory multiple myeloma. This interview took place during the 18th International Myeloma Workshop (IMW 2021) congress.
